Varinder Kaur MD FACP

PubMed

• Characteristics and outcomes of low-grade and high-grade pancreatic immune-related adverse events at a single center.
  Reema Patel, Zakary Kolkey, Joslyn Jung, Omar Elghawy, Abhishek Mullapudi
  Journal of Oncology Pharmacy Practice. 2025-06-11
• 1 citations
  Diagnosis, management, and outcomes of immune checkpoint inhibitor induced acute interstitial nephritis: A single-center experience.
  Omar Elghawy, Reema Patel, Adam Barsouk, Joe Puthumana, Jason Xu
  Journal of Oncology Pharmacy Practice. 2025-06-01
• Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.
  Danny Rischin, Sandro Porceddu, Fiona Day, Daniel P Brungs, Hayden Christie
  The New England Journal of Medicine. 2025-05-31

Journal Articles

• Addressing Opioid-Associated Constipation Using Quality Oncology Practice Initiative Scores and Plan-Do-Study-Act Cycles  
  Varinder Kaur, MD, Sajjad Haider, MD, Appalanaidu Sasapu, MD, Paulette Mehta, MD, Konstantinos Arnaoutakis, MD, Issam Makhoul, MD, Journal of Oncology Practice, 10/31/2016
• PTHrP(12-48) localization is intracellular and it inhibits cell proliferation and osteoclastogenesis  
  Kaur V, Kamalakar A,Akel N, Leitzel K, Allan L, Suva LJ, Cancer Research 75(15 Supplement):1041-1041, 8/1/2015

Abstracts/Posters

• Versatile-002: Overall survival of HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma patients treated with T cell stimulating immunotherapy PDS...
  Jared Weiss, John M Kaczmar, Kevin Joseph Harrington, Ranee Mehra, Francis P Worden, Ralph Zinner, Anshu Giri, Hyunseok Kang, Danh C Pham, Sidra Najeeb, Priyanka Bhate..., Journal of Clinical Oncology/American Society of Clinical Oncology 2025 Annual meeting, 6/1/2025
• 1161 Immunotherapy (IO) associated cardiotoxicity and out-comes with re-challenge
  Nakul Dar, Omar Elghawy, Varinder Kaur, Journal for ImmunoTherapy of Cancer, SITC 39th Annual Conference 2024 (Nov 8-10), Houston, USA, 11/1/2024
• 1468 Evaluation of safety and immunogenicity of a melanoma vaccine, with or without a systemic agonistic CD27 antibody (CDX-1127), in patients with stage II-IV melanoma
  Feifan Xu, Gina R Petroni, Andrew S Poklepovic, Elizabeth Gaughan, Kimberly A Chianese-Bullock, Kelly T Smith, Paul Wright, Jennifer Bryant, Craig L Slingluff, Timothy..., Journal for ImmunoTherapy of Cancer, SITC 39th Annual Conference 2024 (Nov 8-10), Houston, USA, 11/1/2024
• 1466 Phase I/II clinical trial of a melanoma vaccine targeting shared nonmutated antigens and a shared mutated neoantigen with an agonistic CD40 antibody (CDX-1140) pl...
  Emily K Ninmer, Gina R Petroni, Brian Gastman, Elizabeth Gaughan, James M Isaacs, Kathleen Haden, Varinder Kaur, Kimberly A Chianese-Bullock, Kelly T Smith, Paul Wrigh..., Journal for ImmunoTherapy of Cancer, SITC 39th Annual Conference 2024 (Nov 8-10), Houston, USA, 11/1/2024
• 1185 Immunotherapy associated neurotoxicity, and potential re-challenge in select cases: a single center experience
  Jacob S Friedberg, Amrita Ladwa, Omar Elghawy, Mu-Hsun Chen, Zhu Hong, Varinder Kaur, Journal for ImmunoTherapy of Cancer, SITC 39th Annual Conference 2024 (Nov 8-10), Houston, USA, 11/1/2024
• 1165 Spectrum of ocular immune-related adverse events and outcomes with immune checkpoint inhibitor re-treatment
  Tuyet-Minh Tran, Omar Elghawy, Varinder Kaur, Journal for ImmunoTherapy of Cancer, SITC 39th Annual Conference 2024 (Nov 8-10), Houston, USA, 11/1/2024
• 1168 Rare and serious skin toxicity of immune-checkpoint inhibitors: a focus on bullous dermatosis and SJS/TEN
  Mary Kathryn Howard, Varinder Kaur, Journal for ImmunoTherapy of Cancer, SITC 39th Annual Conference 2024 (Nov 8-10), Houston, USA, 11/1/2024
• 1480 Eseba-vec (HB-200) plus pembrolizumab as first-line treatment of recurrent/metastatic HPV16-positive head and neck cancer: updated results in PD-L1 CPS≥ 20 patients
  Alan L Ho, Lisle Nabell, Prakash Neupane, Emrullah Yilmaz, Douglas Laux, Jiaxin Niu, Marshall R Posner, Deborah Wong, Yungpo Bernard Su, Jorge Nieva, Abdul Rafeh Naqas..., Journal for ImmunoTherapy of Cancer, SITC 2024, 11/1/2024
• Tracking Circulating Tumor HPV DNA with Early Cessation of Radiotherapy in Oropharynx Cancer
  ZS Rentiya, J Garneau, V Kaur, PW Read, NS Kalman, KL Fedder, E Dowling, DC Shonka, C McLaughlin, International Journal of Radiation Oncology, Biology, Physics, Washington, D.C., 10/1/2024
• Trial in Progress: CTEP 10492, A Phase 1/1b Study of the AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Squamous Cell Carcinoma
  MD Mattes, H Willers, Y Lin, LA Gharzai, E Alesi, CE Lominska, S Kim, M Haigentz, V Kaur, S Arnold, T Synold, JS Gutkind, L Wirth, A Hanker, R Said, LL Siu, SK Jabbour, International Journal of Radiation Oncology* Biology* Physics, Washington, D.C., 10/1/2024
• 879P VERSATILE-002: Survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous...
  J Weiss, J Kaczmar, KJ Harrington, R Mehra, F Worden, R Zinner, A Giri, H Kang, S Najeeb, T Panella, A Sukari, C Grant, V Kaur, S Jones, D Schaaf, K Price, Annals of Oncology, 9/1/2024
• Real world treatment patterns and outcomes for patients with melanoma brain metastasis: A single center experience
  Amrita Ladwa, Omar Elghawy, Jacob Friedberg, Varinder Kaur, Neuro-Oncology Advances, SNO/ASCO Annual Conference Aug 8-10, 2024, Denver, CO, 8/2/2024
• CTEP 10492, a phase 1/1b study of the AKT inhibitor ipatasertib with chemoradiation for locally advanced head and neck squamous cell carcinoma.
  Malcolm David Mattes, Henning Willers, Yong Lin, Laila A Gharzai, Erin R Alesi, Christopher E Lominska, Sung Kim, Missak Haigentz, Varinder Kaur, Susanne M Arnold, Tim..., Journal of Clinical Oncology, 42;16_suppl:TPS6127-TPS6127, 6/1/2024
• Impact of immune-related adverse events (irAE) onset on disease response and survival in patients (pts) with head-neck cancer treated with immune check point inhibitor...
  Reema Patel, Omar Elghawy, Adam Barsouk, Varinder Kaur, Journal of Clinical Oncology, 42;16_suppl:6028, 6/1/2024
• SDPS-10 DISPARITIES IN THE RISK OF CNS METASTASIS AND CLINICAL OUTCOMES IN PATIENTS WITH HER2- MUTATION POSITIVE (HER2+) NON-BREAST VERSUS HER2+ BREAST CANCERS
  Elghawy O, Horton B, Shen S, Kaur V, Neurooncol Adv, doi: 10.1093/noajnl/vdad070.070. PMCID: PMC10402440., 8/4/2023
• Enrollment Trends Among Patients With Breast Central Nervous System Metastasis in Active Clinical Trials
  Elghawy O, Banfield W, Wang J, Horton B, Kaur V, Cancer Research, Cancer Res (2023) 83 (5_Supplement): P2-13-01., 3/1/2023
• 1269 Immunotherapy (IO) associated acute interstitial nephritis, and outcomes after re-challenge: a single center experience
  Puthumana J, Elghawy O, Horton B, Kaur V, Journal for ImmunoTherapy of Cancer, doi: 10.1136/jitc-2023-SITC2023.1269, 2023
• P2-13-01: Enrollment Trends Among Patients With Breast Central Nervous System Metastasis in Active Clinical Trials
  Elghawy O, Banfield W, Wang J, Horton B, Kaur V, Cancer Res, 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, Philadelphia (PA), 12/6/2022
• Phase I study of M6620 (VX-970, berzosertib) in combination with cisplatin and XRT in patients with locally advanced head and neck squamous cell carcinoma
  A. Bhatia, Z. Chen, J. Bruce, C.E. Steuer, D.P. Zandberg, J.W. Riess, D. Mitchell, T.H. Davis, M. Patel, V. Kaur, S. Arnold, T.K. Owinokoko, Annals of Oncology, Annals of Oncology (2022) 33 (suppl_7): S295-S322. 10.1016/annonc/annonc1056, 9/10/2022
• CLRM-11 Current State of Clinical Trials for patients with melanoma brain metastases
  Elghawy O, Banfield W, Horton B, Kaur V, Neurooncology Advances, SNO/ASCO Annual Conference, Toronto, Canada, 8/5/2022
• Current State of clinical trials for patients with melanoma brain metastasis
  Elghawy O, Banfield W, Horton B, Kaur V, Neuro-oncology Advances, Neurooncol Adv. 2022 Aug; 4(Suppl 1): i8. doi: 10.1093/noajnl/vdac078.031, 8/2022
• 656MO Phase I study of M6620 (VX-970, berzosertib) in combination with cisplatin and XRT in patients with locally advanced head and neck squamous cell carcinoma
  Bhatia A, Chen Z, Bruce J, Steuer CE, Zandberg DP, Riess JW, Mitchell D, Davis TH, Patel M, Kaur V, Arnold S, Owonikoko TK, Annals of Oncology 33, S842, ESMO 2022, 2022
• A trial to evaluate the safety, immunogenicity, and clinical activity of a helper peptide vaccine plus PD-1 blockade (Mel64, PATHVACS: PD-1 antibody and T-helper vacci...
  Craig Slingluff, Kimberly Chianese-Bullock, Ileana Mauldin, Walter Olson, Kelly Smith, Lynn Dengel, Kathleen Haden, Elizabeth Gaughan, Varinder Kaur, William Grosh, Journal for ImmunoTherapy of Cancer, Volume 9, Issue suppl 2, 11/1/2021
• Outcome disparities in rural versus urban patients with head and neck cancer: Leveling the playing field
  Varinder Kaur, Anthony Rooney, Desai Raj Piyush, Journal of Clinical Oncology, Journal of Clinical Oncology 39, no. 15_suppl, 5/28/2021
• A trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC
  Slingluff CR, Petroni GR, Chianese-Bullock KA, Wages NA, Walson CO, Smith KT, Dengel LT, Dickinson A, Reed C, Gaughan EM, Grosh WW, Kaur V, Varghegyi N, Smolkin ME, Ga..., SITC 2019, Nov 6-10, 2019; p365, National Harbor, Maryland, 11/8/2019
• Join now to see all